A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00152087 |
Recruitment Status : Unknown
Verified September 2005 by St. Joseph's Hospital, Florida.
Recruitment status was: Recruiting
First Posted : September 9, 2005
Last Update Posted : September 9, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Cancer | Device: Brachytherapy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 25 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol. |
Study Start Date : | October 2002 |
Study Completion Date : | June 2005 |

- Efficacy
- - Response to treatment
- - Survival time from treatment
- Safety:
- - Adverse experience

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Over 18 years of age of any sex, race
- Histological proof of HCC
- Able to give Informed Consent
- ECOG performance equal or less than 2
- Life expectancy equal to or greater than 3 months
- Non- pregnant with acceptable contraception in premenopausal women
- Greater than 4 weeks since prior radiation therapy or surgery
- 1 month post chemotherapy
- Serum Bilirubin < 2.0
- Acceptable white blood count
Exclusion Criteria:
- Co-morbid disease that would place patient at undue risk.
- Pre-existing diarrhea/illness
- Pregnant
- Fail preliminary MAA testing

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00152087
Contact: Mary Pritchard, RN, OCN | 813-870-4257 | Mary.Pritchard@baycare.org | |
Contact: Ronda Buffington, RN, OCN | 813-870-4123 | Ronda.buffington@baycare.org |
United States, Florida | |
St. Joseph's Hospital | Recruiting |
Tampa, Florida, United States, 33607 | |
Contact: Ronda Buffington, RN,OCN 813-870-4123 Ronda.Buffington@baycare.org | |
Contact: Mary Pritchard, RN, OCN 813-870-4257 Mary.Pritchard@baycare.org |
Principal Investigator: | Alison R. Calkins, MD | St. Joseph's Hospital, Tampa, FL |
ClinicalTrials.gov Identifier: | NCT00152087 |
Other Study ID Numbers: |
SJCI015 Alison Calkins, MD Matthew Berlet, MD |
First Posted: | September 9, 2005 Key Record Dates |
Last Update Posted: | September 9, 2005 |
Last Verified: | September 2005 |
Liver cancer Brachytherapy |
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Liver Diseases |